Nigeria, the most populous Black country in the world, though it has contributed to the welfare of other African countries, is plagued by internal conflicts with small arms. Over a million illegal small arms circulate in Nigeria in the hands of militant groups. Over 10,000 may have died in conflicts between these groups and the government. Quality health care is unavailable in much of the country, and small arms injuries often overstretch emergency health care. A national committee has been set up to implement the ECOWAS moratorium on small arms and light weapons, but much remains to be done.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/13623690500270929 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of Lower-Volume Training on Physical Fitness Adaptations in Team Sports Players: A Systematic Review and Meta-analysis.
Sports Med Open
January 2025
Department of Sports Science and Clinical Biomechanics, SDU Sport and Health Sciences Cluster, University of Southern Denmark, Odense, Denmark.
Background: A small number of reviews have explored lower- versus higher-volume training in non-athletes, but the growing challenge of congested schedules in team sports highlights the need to synthesize evidence specific to team sport athletes. Thus, the objectives of this systematic review with meta-analysis are twofold: (i) to summarize the primary physiological and physical fitness outcomes of lower-volume versus higher-volume training interventions in team sports players; and (ii) to compare the effects of lower-volume training with higher, considering the training modalities used.
Methods: We conducted searches across key databases, including PubMed, Scopus, SPORTDiscus, and Web of Science.
Thoracoscopic anatomical sublobar resection for deep interlobar lung cancer with fused fissure.
J Thorac Dis
December 2024
Department of Thoracic Surgery, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Background: The technical challenges associated with the removal of small nodules in challenging locations rather than peripheral locations remain unaddressed. We sought to illustrate the parenchymal-sparing surgical approach employed for deep interlobar lung cancer with fused fissures (DILCFFs).
Methods: A retrospective review of 43 patients with cT1N0M0 DILCFFs from January 2013 through December 2022 was performed.
Osimertinib as a neoadjuvant therapy in resectable EGFR-mutant non-small cell lung cancer: a real-world, multicenter retrospective study.
Transl Lung Cancer Res
December 2024
Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China (UESTC), Chengdu, China.
Background: Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), has been authorized for use in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). This study aimed to evaluate the effectiveness and safety of neoadjuvant osimertinib in individuals with resectable locally advanced NSCLC harboring EGFR mutation.
Methods: Ten centers located in mainland China took part in a single-arm, real-world, multicenter retrospective study (registration number: ChiCTR2100049954).
Health-related quality of life analysis from ENTER, a randomized, controlled phase III trial of whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases.
Transl Lung Cancer Res
December 2024
Department of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Background: Health-related quality of life (HRQoL) is critical for patients with lung cancer due to poor prognosis. We presented patient-reported outcomes in patients with non-small cell lung cancer (NSCLC) brain metastases (BM) who received whole-brain radiotherapy (WBRT) in combination with erlotinib or WBRT alone in the phase 3 ENTER study.
Methods: The patients' HRQoL was assessed by using the European Organization for Research and Treatment of Cancer 30-item Core Quality of Life Questionnaire (EORTC QLQ-C30).
Efficacy, safety, and quality of life of dabrafenib plus trametinib treatment in Chinese patients with mutation-positive metastatic non-small cell lung cancer.
Transl Lung Cancer Res
December 2024
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Background: Dabrafenib plus trametinib (Dab + Tram) is an approved targeted therapy in patients with mutated metastatic non-small cell lung cancer (NSCLC). Here, we report the efficacy, safety, and quality of life (QoL) results of Dab + Tram treatment in Chinese patients with mutation-positive metastatic NSCLC.
Methods: This is a single-arm, open-label, multicentre, phase II study (NCT04452877).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!